<DOC>
	<DOCNO>NCT03014947</DOCNO>
	<brief_summary>This phase I , randomize , double-blind , parallel-group trial compare Investigation Medicinal Product ( IMP ) MSB11022 , US- Reference Product ( RP ) , EU- Reference Medicinal Product ( RMP ) ( Humira® ) healthy subject .</brief_summary>
	<brief_title>MSB11022 Healthy Subjects</brief_title>
	<detailed_description />
	<mesh_term>Adalimumab</mesh_term>
	<criteria>Healthy male subject healthy female subject nonchildbearing potential age 18 55 year , inclusive . Other protocol define inclusion criterion could apply . Concurrent history infection opportunistic infection , include sepsis , pneumonia , fungal infection . Individuals history tuberculosis diagnose tuberculosis interview , chest Xray examination , interferongamma release assay . Concurrent history demyelinate disease ( multiple sclerosis , etc. ) . Concurrent history congestive cardiac failure . Concurrent history allergic symptom asthma bronchial , druginduced rash , urticaria , , judgment investigator , may affect participation clinical study . Concurrent history cardiac , hepatic , renal , gastrointestinal , respiratory , and/or hematological function disorder , , judgment investigator sub investigator , may affect participation clinical study . Other protocol define exclusion criterion could apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>MSB11022</keyword>
	<keyword>Humira®</keyword>
</DOC>